Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embeda Uptake In Primary Care Depends On FDA Clearing Marketing Materials, King Says

This article was originally published in The Pink Sheet Daily

Executive Summary

After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.

You may also be interested in...



King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"

Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.

King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"

Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.

King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?

King Pharmaceuticals expects up-or-down vote on formulation of immediate-release oxycodone with niacin. King will resubmit Acurox application after meeting.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel